Anteris welcomes successful DurAVR valve-in-valve procedure

–News Direct–

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson tells Proactive the companys flagship transcatheter heart valve has been successfully implanted during a valve-in-valve procedure as part of Health Canadas Special Access Program (SAP).

The procedure is used in life-threatening situations where a patients bioprosthetic aortic valve is failing due to calcification or structural deterioration, meaning a new heart valve must be implanted inside the failing valve. Paterson says the successful procedure further validates the companys extensive pre-clinical valve-in-valve work as well as its clinical experience in native aortic stenosis.

Dr Anita Asgar, co-director of the Structural Heart Program at the Institut de Cardiologie de Montreal, asked to use the DurAVR valve given the need for optimal hemodynamic results.

Dr Asgar said using Anteris ComASUR delivery system and deploying the valve was remarkably easy.

The unique design of DurAVR, including the low frame height and the single-piece design, makes the valve well-suited to address the needs of valve-in-valve patients, she concluded.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

Anteris Technologies Ltd

comtex tracking


About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Gio News UK journalist was involved in the writing and production of this article.